In my penultimate Barchart article for the year 2025, I am revisiting Indivior (INDV), a Virginia-based company specializing in opioid addiction treatments. Previously, I covered this company in early September when it had just climbed 11 spots on Barchart’s Top 100 Stocks to Buy list. Now, as of Monday, the stock has risen even further, up 12 spots to 38th place, showcasing its continued upward momentum.
Over the past year, Indivior’s stock price has soared by nearly 200%, with a significant portion of those gains occurring in the three months following my September article. This remarkable growth has caught the attention of investors who are now questioning whether the company can sustain this momentum into 2026.
One of the key factors driving Indivior’s success is its improving financial performance. As the company becomes more profitable and introduces new treatments to its portfolio, its price-to-earnings ratio continues to decline, signaling a positive trend for shareholders.
Looking ahead to 2026, there are several reasons why Indivior stock has a strong chance of continuing its upward trajectory. In fiscal 2025, the company posted impressive profits, with a substantial portion coming from its flagship product, Sublocade. This once-monthly injection for opioid addiction has been a major revenue driver, contributing 68% of the company’s net revenue in the first half of the year.
Indivior’s guidance for 2025 forecasts robust revenue and adjusted EBITDA figures, with expectations of $1.2 billion in revenue and $410 million in adjusted EBITDA. These projections represent significant increases from previous estimates, indicating the company’s strong growth prospects.
Furthermore, Indivior’s recent inclusion in the S&P SmallCap 600 Index underscores its growing reputation as a high-quality player in the pharmaceutical industry. CEO Joe Ciaffoni’s strategic vision for the company, coupled with key hires like CCO Pat Barry, positions Indivior for continued success in the coming year.
Barry’s focus on expanding Indivior’s market share in the long-acting injectables (LAI) segment, particularly with Sublocade, bodes well for the company’s future growth. By streamlining its operations and reducing annual expenses, Indivior is poised to maximize its resources and drive further innovation in its product offerings.
Analysts are optimistic about Indivior’s prospects, with a consensus Buy rating and an average 12-month target price of $37.86. As the company executes its commercialization plans and attracts more analyst coverage, there is potential for higher multiples and a rise in share price.
In conclusion, while healthcare stocks may not always elicit excitement, Indivior’s focus on opioid treatments and expansion into the LAI market present a compelling investment opportunity. With a solid track record of growth and a clear strategy for the future, buying into Indivior at the current price could prove to be a winning decision over the next few years.
